A two-and-a-half-year-old girl was successfully treated for a rare genetic motor neuron disease. In a groundbreaking study, the patient began receiving the treatment while still in the womb.
The mother took a drug that directly targeted the disease, spinal muscular atrophy, and the girl continues to take it.
Spinal muscular atrophy is a genetic disorder that targets the motor neurons, limiting movement and weakening muscles over time. The disease is sporadic, occurring in one out of every 10,000 people.
Michelle Farrar, a pediatric neurologist at UNSW Sydney in Australia said the “baby has been effectively treated, with no manifestations of the condition”.
Rare Genetic Disease treated in the womb could change medicine forever
A two-and-a-half-year-old girl shows no signs of a rare genetic disorder, after becoming the first person to be treated with a gene-targeting drug while in the womb for spinal muscular atrophy, a motor neuron disease. The “baby has been effectively treated, with no manifestations… pic.twitter.com/735ivKDHkW
— Professor Erwin Loh (@erwinloh) February 20, 2025
The world’s first treatment highlights the significance of early intervention, as the window to treat such a disease and others like it is extremely limited.
The case shows “how important early treatment is,” said Farrar. “The therapeutic window that we’re targeting is very narrow.”
The girl had the most severe form of this genetic disorder, as it affects each individual differently. In her case, she lacked both copies of the SMN1 gene and had only one or two copies of the adjacent SMN2 gene. In other instances, it has been known to compensate for the absence of the former. Without this gene, insufficient amounts of the specific protein necessary for maintaining healthy motor neurons in the spinal cord and brainstem are produced.
The protein’s production window is most significant during the second and third trimesters of pregnancy and the first months of the baby’s life. For this reason, people born with this disease often don’t live to more than three years old.
The drug used in this study is named Ridisplam, one of three approved by the Food and Drug Administration (FDA). Swiss biotech firm Roche produces the orally administered drug. It is a small molecule that increases the ability of the SMN2 gene to make the necessary SMN protein that people with spinal muscular atrophy lack. The mother in this case took the drug starting at 32 weeks of pregnancy for six weeks. The baby began taking it at one year old and will continue for the rest of her life.
The idea of administering the drug during pregnancy was a request of the parents. Most babies who are given this drug still have some of the symptoms and the couple had already lost a child to the disease before.
“They had already experienced a loss from this horrible disease,” said Richard Finkel, the study lead and a clinical neuroscientist at St. Jude Children’s Research Hospital in Memphis, Tennessee. Finkel added that the parents wished to see their options, and the FDA approved the treatment during utero for this specific case alone.
The success of this treatment could lead to more approvals for other parents seeking to follow in this family’s footsteps. Finkel states that this also could lead the way for more genetic diseases to be treated in the womb and the approval of studies relating to such treatment.
See all the latest news from Greece and the world at Greekreporter.com. Contact our newsroom to report an update or send your story, photos and videos. Follow GR on Google News and subscribe here to our daily email!


